Right Ventricular Lead Placement in a Pacemaker Population: Evaluation of Apical and Alternative Position
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01647490|
Recruitment Status : Unknown
Verified July 2012 by Carmine Muto, Ospedale Santa Maria di Loreto Mare.
Recruitment status was: Recruiting
First Posted : July 23, 2012
Last Update Posted : July 23, 2012
|Condition or disease||Intervention/treatment||Phase|
|Bradycardia Heart Block Sick Sinus Syndrome||Procedure: Permanent Cardiac Pacemaker Implantation||Not Applicable|
Permanent cardiac pacing plays an important role in cardiac disease management. Since early studies on right ventricular pacing, apex has been the preferred implant site for transvenous endocardial ventricular leads for several reasons: ease of placement, lead stability as well as the design characteristics of the electrode and the fixation system.
It is now also accepted, however, that right ventricle pacing causes a long term deterioration of left ventricular function through complex effects, both at the structural level of the heart wall and at the hemodynamic level in left ventricular load conditions. It is possible that this deterioration is due to a dyssynchrony of contraction induced by pacing at the right ventricular apex. Some authors suggest to pace the right ventricle at alternative sites, i.e. the medium septum (RVS) region, to guarantee a more physiological activation pattern, especially in patients expected to receive high pacing percentages.
However, unequivocal evidences that stimulation of the right ventricular septum is more physiological than the apical pacing are still missing.
Nonetheless, it should be noted that, although a number of studies refer to RV septum as the alternative site for pacing , poor attention has been paid to the unambiguous definition of RV septum region itself. A clear definition and a proper evaluation of the alternative site is therefore important.
Furthermore, from a procedural point of view, it has been demonstrated that acute and chronic electrical performances of the leads positioned at alternative sites, in particular in the region of mid septum, are equivalent to those of the leads positioned at the apical site.
The purpose of this study is to perform a comprehensive assessment of the electrical and mechanical measures obtained by pacing standard RV site (Right ventricular apex, RVA) and alternative RV site (right ventricular septum, RVS). Specifically, the two pacing sites will be compared in terms of electrical dyssynchrony, as assessed by ECG criteria, and in terms of mechanical dyssynchrony, as assessed by echocardiographic criteria.
The primary end point of the study is defined through the evaluation of dyssynchrony measured both in spontaneous rhythm (Vs) and paced rhythm (Vp). The delay between the time to peak systolic velocity of the septum and the LV free wall will be used to define the degree of dyssynchrony; this measurement will be obtained by TDI echocardiographic technique.
Patients will receive any commercially available dual-chamber implantable pacemakers, according to current standard indications. At the end of the implantation and at follow-up visits (12 and 24 months) device programming will follow the clinical practice of the center.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||408 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Participant, Outcomes Assessor)|
|Official Title:||Right Ventricular Lead Placement in a Pacemaker Population: Evaluation of Apical and Alternative Position - Right Pace Study|
|Study Start Date :||April 2012|
|Estimated Primary Completion Date :||July 2013|
|Estimated Study Completion Date :||July 2015|
Active Comparator: Right Ventricular Apex (RVA)
In the RVA group the right ventricular pacing lead will be implanted in the apex region of the right ventricle
|Procedure: Permanent Cardiac Pacemaker Implantation|
Experimental: Right Ventricular Septum (RVS)
In the RVS group the right ventricular pacing lead will be implanted in the septal region (mid septum) of the right ventricle
|Procedure: Permanent Cardiac Pacemaker Implantation|
- LV dyssynchrony as measured by Electromechanical delay (EMD [ Time Frame: 2 weeks ]The primary outcome measure of this study is to compare the effect of RV Septal (RVS) versus RV Apical (RVA) pacing as measured by echocardiographic/Doppler Index
- Number of heart failure-related hospitalization [ Time Frame: 24 months ]To compare the rate of heart failure-related hospitalization between RVS versus RVA pacing
- Right ventricular lead and total implant procedure time, fluoroscopy time [ Time Frame: Implant ]To compare the procedural time of RVS versus RVA pacing
- Change from baseline in R wave in 12-lead ECG [ Time Frame: 24 months ]To investigate the relationship between the ECG characteristics at baseline and response to cardiac pacing (as measured by echocardiography as defined in primary outcome measure) at implant and 24 months
- Absolute change in LVEF [ Time Frame: 24 months ]To evaluate the Left ventricular diastolic and systolic function as measured by Echocardiographic response of absolute change in LVEF
- LV dyssynchrony as measured by Electromechanical delay (EMD) [ Time Frame: 24 months ]The secondary outcome measure of this study is to compare the effect of RVS versus RVA pacing as measured by echocardiographic/Doppler Index. This extends to 24 months the results obtained with the primary objective at 2 weeks
- Symptoms and quality of life scores [ Time Frame: 24 months ]To investigate the relationship between the right ventricular lead position and response to cardiac pacing in terms of symptoms and quality of life scores as measured by short form (SF)-12 scores
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01647490
|Azienda Ospedaliero Universitaria "Vittorio Emanuele"||Recruiting|
|Catania, Italy, 95124|
|Contact: Valeria Calvi, MD firstname.lastname@example.org|
|Principal Investigator: Valeria Calvi, MD|
|Ospedale Santa Maria di Loreto Mare||Recruiting|
|Naples, Italy, 80142|
|Contact: Carmine Muto, MD email@example.com|
|Principal Investigator: Carmine Muto, MD|
|Study Chair:||Carmine Muto, MD||Ospedale Santa Maria di Loreto Mare|
|Study Chair:||Valeria Calvi, MD||Azienda Ospedaliero Universitaria "Vittorio Emanuele" - Ferrarotto|